Roger Guillemin
| Category | Research |
|---|---|
| Also known as | Roger Charles Louis Guillemin |
| Last updated | 2026-04-14 |
| Reading time | 3 min read |
| Tags | scientisthypothalamic-hormonesnobel-prizesomatostatinTRH |
Overview
Roger Guillemin (January 11, 1924 – February 21, 2024) was a French-born American neuroendocrinologist whose laboratory, competing fiercely with that of Andrew Schally, isolated and characterized several hypothalamic releasing and inhibiting hormones. He shared the 1977 Nobel Prize in Physiology or Medicine with Schally and Rosalyn Yalow.
Guillemin's most celebrated contributions include the isolation of thyrotropin releasing hormone (TRH), gonadotropin releasing hormone (GnRH), and — especially — somatostatin, which his team identified in 1973 while searching for a growth hormone releasing factor. Later work on endorphins and growth hormone releasing hormone further extended the catalog of hypothalamic peptides.
Guillemin was famous for his enormous-scale extraction campaigns. The TRH work alone reportedly required processing hundreds of thousands of sheep hypothalami. He moved from Baylor College of Medicine in Houston to the Salk Institute in La Jolla in 1970 and subsequently held positions at the Whittier Institute and the Scripps Research Institute.
Background
Guillemin was born in Dijon, France, and studied medicine at the University of Dijon and the University of Lyon. He worked under Hans Selye in Montreal for his Ph.D. and then joined Baylor in Houston before moving to Salk. His scientific style combined meticulous organic chemistry with vast resources for handling animal tissue at industrial scale.
His rivalry with Schally produced both major advances and considerable personal friction. Both men ultimately received the Nobel Prize together, but the public record of their competing laboratories — recounted in Nicholas Wade's book The Nobel Duel — remains a case study in the sociology of modern biomedical research.
Key Contributions
- Isolation and sequencing of TRH (1969).
- Isolation of GnRH (LHRH) (1971).
- Isolation of somatostatin (1973).
- Characterization of alpha- and beta-endorphins and their release by the pituitary.
- Isolation of growth hormone releasing hormone (GHRH, 1982).
Timeline
- 1924: Born in Dijon, France.
- 1949: Medical degree from the University of Lyon.
- 1953: Joins Baylor College of Medicine.
- 1969: Reports TRH structure.
- 1970: Moves to the Salk Institute.
- 1971: Reports GnRH.
- 1973: Reports somatostatin.
- 1977: Shares the Nobel Prize.
- 1982: Reports GHRH.
- 2024: Dies at age 100.
Modern Relevance
Guillemin's hypothalamic peptide discoveries underpin much of modern endocrinology and reproductive medicine. GnRH analogs are used for prostate cancer, endometriosis, fibroids, precocious puberty, and assisted reproduction. Somatostatin analogs (octreotide, lanreotide, pasireotide) treat acromegaly and neuroendocrine tumors. TRH remains an important research and diagnostic tool.
Beyond specific drugs, Guillemin's work established that the hypothalamus governs the pituitary through a well-defined chemical language and that this language consists of discrete peptides with highly specific actions. This framework continues to guide neuroendocrine research. See andrew-schally and nobel-prize-hypothalamic-hormones for related history.
Related Compounds
Related entries
- Andrew Schally— Andrew Schally is a Polish-American neuroendocrinologist who shared the 1977 Nobel Prize for isolating hypothalamic peptide hormones.
- The 1977 Nobel Prize for Hypothalamic Hormones— Roger Guillemin and Andrew Schally shared half of the 1977 Nobel Prize for isolating TRH, GnRH, and other hypothalamic peptide hormones.
- The Discovery of Somatostatin— Somatostatin, the hypothalamic peptide that inhibits growth hormone release, was identified in 1973 by Brazeau and Guillemin.